Drug Profile
Devextinetug - InterveXion Therapeutics
Alternative Names: Anti-methamphetamine chimeric monoclonal antibody - InterveXion Therapeutics; Anti-methamphetamine monoclonal antibody; Ch-mAb7F9; IXT-m200; METH-mAbLatest Information Update: 19 Jan 2023
Price :
$50
*
At a glance
- Originator University of Arkansas for Medical Sciences
- Developer InterveXion Therapeutics
- Class Drug withdrawal therapies; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Substance-related disorders
Most Recent Events
- 05 Jan 2023 InterveXion Therapeutics terminates a phase II Meth-OD trial in Substance-related disorders in USA (IV) (NCT04715230)
- 25 Apr 2022 InterveXion Therapeutics and the National Institute on Drug Abuse initiates a phase II trial in Substance related disorders in USA (IV) (NCT05034874)
- 18 Mar 2022 InterveXion Therapeutics and the National Institute on Drug Abuse completed the phase I trial in Substance related disorders (In volunteers) in USA (IV) (NCT05027451)